Deprescribing in older adults- What we know

Episode Overview: Deprescribing is not the withdrawal of care—it is a sophisticated, highly planned, and person-centred element of good prescribing. In this episode of Synapse, we unpack the clinical mechanics of safely reducing or stopping medications in older adults experiencing polypharmacy. Drawing directly from the latest Western Australian Centre for Health and Ageing (WACHA) Clinical Practice Guidelines, we move past broad generalizations to give you the exact timelines, step-down formulas, and safety-netting protocols you need for your next consult.

What We Cover in This Episode:

• The Deprescribing Framework: How to approach the structured medication review using the lenses of indication, benefit, harm, and patient-specific goals.
• The Absolute Red Flags: The critical clinical boundaries you cannot cross without specialist input—including the absolute non-negotiables of Denosumab management, the 2-year antiepileptic rule, and managing SGLT2i/GLP-1 therapies for cardiovascular protection independent of HbA1c.
• Class-Specific Tapering Blueprints: A granular breakdown of which common medications can be stopped cold (like iron, calcium, or oral hypoglycaemics) versus the precise step-down protocols required for PPIs, Cholinesterase Inhibitors, high-dose loop diuretics, and Benzodiazepines.
• Mastering the Follow-Up: How to confidently identify Adverse Drug Withdrawal Events (ADWEs)—such as withdrawal-emergent extrapyramidal movements or rebound acid hypersecretion—and execute an airtight GP monitoring schedule to support your patients safely.

GP Fellowship exams, AMC MCQ Recalls, AMC Clinical Exam criteria, Australian therapeutic guidelines, PESCI preparation. 

⚠️ Disclaimer: The voices in this podcast are AI-generated. This content is produced for educational and learning purposes only and does not constitute medical advice. Clinical decisions should always be made in accordance with current guidelines, individual patient circumstances, and in consultation with appropriate colleagues and specialists.

Transcript

SPEAKER_01 0:00

What if the exact prescription that saved your patient's life at 60 is um the very thing putting them at risk of a fatal life-ending fall at 85?

SPEAKER_00 0:10

Aaron Powell I mean, it is the ultimate prescribing paradox, really.

SPEAKER_01 0:13

Right.

SPEAKER_00 0:13

The evidence-based guidelines that dictate how we treat a robust middle-aged adult. Right. Well, they can become an active biological liability when applied to a frail octagenarian.

SPEAKER_01 0:23

Aaron Powell Welcome to this deep dive. Today we are speaking directly to you, uh, our fellow general practitioners and registrars managing the complexities of primary care.

SPEAKER_00 0:33

Absolutely.

SPEAKER_01 0:34

Our mission today is mastering the art and the very precise science of deprescribing in older adults. We're going to break down the exact timelines, the specific medication classes, and you know, the pharmacology of dismantling a prescribing cascade.

SPEAKER_00 0:47

Aaron Powell Because we really need to define what we're actually doing here. Deprescribing is not the withdrawal of care.

SPEAKER_01 0:55

No, not at all.

SPEAKER_00 0:55

It's not throwing our hands up and giving up on a patient. It is a highly active, planned, and person-centered element of good prescribing.

SPEAKER_01 1:03

It's the necessary other side of the prescribing coin, and the clinical reasoning required to do it safely is immense.

SPEAKER_00 1:10

It really is. What we're doing is dynamically assessing how a patient's changing physiology. So decreased renal clearance, altered body fat distribution, uh, shifting receptor sensitivities, how all of that changes the risk-benefit balance of every single drug on their list.

SPEAKER_01 1:28

Aaron Powell Yeah, the physiology's a moving target.

SPEAKER_00 1:30

Exactly. And what's fascinating here is how the clinical math changes entirely when a patient's life expectancy falls below one year. Suddenly, the time to benefit for preventative therapies, well, it completely exceeds their remaining lifespan.

SPEAKER_01 1:44

Okay, let's unpack this for a second. If you prescribe a bisphosphonate for primary prevention of a fracture, the preventative payoff biologically takes, what, about three to five years to materialize? Roughly. So if the patient's life expectancy is realistically less than one year, we're subjecting them to the immediate daily risks of the medication.

SPEAKER_00 2:01

Right, the severe reflux, the rigid morning administration protocol. Exactly. All for a skeletal benefit they will likely never live to see.

SPEAKER_01 2:10

And that drastically shifts our clinical goalposts from long-term prevention to immediate quality of life. But navigating that shift with the patient requires an incredibly delicate touch.

SPEAKER_00 2:21

It really does. It's a tough conversation.

SPEAKER_01 2:23

Which brings me to an analogy I always use with my registrars. When you look at a mature sprawling tree in your backyard, your first instinct to keep it healthy isn't to just keep dumping more and more fertilizer on it.

SPEAKER_00 2:34

No, of course not.

SPEAKER_01 2:35

At a certain point, to ensure the core of the trunk stays structurally sound, you have to do some strategic pruning.

SPEAKER_00 2:42

I love that analogy.

SPEAKER_01 2:43

You remove the dead weight, the branches that are no longer serving a purpose, or the ones that are actively damaging the tree. You aren't harming the tree by pruning it. You know, you're preserving its longevity. But realistically, as a GP, it is logically very easy to look at the clinical software, see the polypharmacy, and say, let's stop this.

SPEAKER_00 3:04

Well, software makes it look so simple.

SPEAKER_01 3:05

Right. But across the desk, patients often feel like we're taking something vital away. I mean, they've been told for a decade that this little white pill keeps their heart ticking. So how do we practically frame that in a standard consultation so they don't feel abandoned?

SPEAKER_00 3:21

Well, you have to anchor the conversation and they're evolving biology rather than simply telling them the drug is uh bad now. Right. I find it highly effective to say, look, your body has changed, your kidneys are processing things differently, and right now this medication is doing more harm than good.

SPEAKER_01 3:38

Aaron Powell That shifts the blame away from them or even the drug to just the natural aging process.

SPEAKER_00 3:43

Aaron Powell Exactly. But the most crucial safety net you can offer to lower the emotional stakes is the concept of a trial. Remind them that deprescribing is not a permanent, irreversible door.

SPEAKER_01 3:53

It's not a one-way street.

SPEAKER_00 3:55

Right. We are stepping the dose down as a clinical trial. If their symptoms return and it's clinically indicated, we can restart the medicine at any time with their informed consent.

SPEAKER_01 4:04

It transforms a terrifying loss of control into a collaborative experiment.

SPEAKER_00 4:08

Yeah, it completely lowers the temperature of the consult.

SPEAKER_01 4:11

It really does. But before we start pruning that medication tree, we have to know exactly which branches are load-bearing.

SPEAKER_00 4:18

Oh, absolutely. If we cut the wrong branch, the whole physiological structure comes crashing down.

SPEAKER_01 4:23

So let's transition into the absolute contraindications, the red flags. These are the high-stakes clinical scenarios where routine deprescribing and general practice is downright dangerous without specialist input.

SPEAKER_00 4:36

We have to start with the absolute highest risk red flag on our list.

SPEAKER_01 4:42

Oh, yes.

SPEAKER_00 4:42

This biologic agent frequently trips up even highly experienced clinicians. You must never, ever withhold a scheduled dose of dinosumab simply to trial deprescribing.

SPEAKER_01 4:54

I cannot emphasize that enough to the registrars listening. Never delay or skip a dose.

SPEAKER_00 4:58

The risk of rebound vertebral fractures is severe, rapid, and frankly devastating.

SPEAKER_01 5:03

But let's explain the biology of why that happens, because it's not a classical drug withdrawal, is it?

SPEAKER_00 5:07

No, it comes down to the mechanism of action. Denosumab is a rank ligand inhibitor. It powerfully suppresses osteoclast formation and function, effectively freezing bone resorption.

SPEAKER_01 5:17

Right.

SPEAKER_00 5:17

But unlike bisphosphonates, which embed themselves into the bone matrix for years, DinoSumab does not. The moment that monoclonal antibody clears the system, the Arank ligand is entirely uninhibited. You get this massive, immediate resurgence of aggressively active osteoclasts.

SPEAKER_01 5:35

So the bone turnover markers just skyrocket?

SPEAKER_00 5:37

These skyrocket far above the patient's baseline, and the microarchitecture of the vertebrae can literally collapse within months.

SPEAKER_01 5:44

Wow. So if a GP and their patient explicitly decide to cease denosumab, what is the exact mandatory protocol to prevent that osteoclast surge?

SPEAKER_00 5:54

You must forcibly stabilize the bone turnover. To do that, you transition them to bisphosphaneate therapy, either two months before the next scheduled denosumab dose or exactly at the time the dose is due.

SPEAKER_01 6:05

Okay, so timing is critical.

SPEAKER_00 6:06

Extremely. And that bisphosphonate must be continued for a minimum of 12 months. Do not attempt this without a rigid, diary alerted plan in place.

SPEAKER_01 6:14

That is a critical clinical pearl. Now, another drug class that causes a lot of anxiety in the clinic is antiepileptics. I see this frequently. A patient in their 70s hasn't had a seizure in five years, and they're understandably tired of the cognitive blunting and the lethargy caused by the medication, they want off.

SPEAKER_00 6:31

It's totally understandable. But the physiological seizure threshold in the aging brain can be highly unpredictable. So what's the rule? The strict rule here is a minimum two-year seizure-free period before you can even entertain the idea of deprescribing for an epilepsy indication.

SPEAKER_01 6:48

Two full years.

SPEAKER_00 6:49

At least. And even then, it mandates neurologist input. You cannot do this solo in the GP clinic. You need a formal documented seizure action plan in place before you initiate any sort of taper.

SPEAKER_01 7:01

And beyond the neurology, there is the massive psychosocial hurdle. You have to have a very frank discussion about the implications for their driving license.

SPEAKER_00 7:09

Oh, the legalities are incredibly strict. If they experience a breakthrough seizure during the taper, they lose their driving license immediately, often for a prolonged period.

SPEAKER_01 7:18

Yeah, that's a huge blow to independence.

SPEAKER_00 7:20

It is. When you explain that a failed taper might cost them their ability to drive, many patients actually choose to remain on the medication.

SPEAKER_01 7:29

It changes the entire risk-benefit calculus for them. Now let's look at organ protection versus symptom control, particularly in the realms of heart failure and diabetes. I want to look at where registrars often get tripped up.

SPEAKER_00 7:42

If we connect this to the bigger picture, we really have to separate drugs that superficially manage numbers on a pathology report from drugs that fundamentally alter cellular mortality.

SPEAKER_01 7:52

Give me an example.

SPEAKER_00 7:53

For instance, in heart failure with reduced ejection fraction. So HFREF, we must continue aldosterone antagonists like spironolactone. Right. The neurohormonal blockade they provide prevents adverse cardiac remodeling. The mortality and hospitalization benefits are just too significant to risk withdrawing.

SPEAKER_01 8:12

Even if the patient's daily fluid status looks perfectly stable.

SPEAKER_00 8:15

Exactly. Even if they aren't clinically congested, you keep it going.

SPEAKER_01 8:19

Let me introduce a classic clinical dilemma here. You have a type 2 diabetic patient. Over the last year, they've made amazing lifestyle changes, maybe lost some weight. Their HBA1C comes back perfectly on target, well under 7%.

SPEAKER_00 8:33

A great result.

SPEAKER_01 8:34

Right. But to a first-year registrar trying to reduce polypharmacy, the immediate instinct is going to be to pull back the SGLT2 inhibitor or the GLP1 analog. Why is that the wrong move?

SPEAKER_00 8:46

Aaron Powell Because that instinct assumes those drugs are just fancy blood glucose lowerers. Those specific classes, SGLT2 inhibitors and GLP1 analogs, have profound pleotropic effects.

SPEAKER_01 8:57

Aaron Powell Meaning they do a lot more than just drop the sugar.

SPEAKER_00 9:00

Trevor Burrus Exactly. If they were originally prescribed for cardiovascular or renal protection, they must be continued independent of the HBA1C level.

SPEAKER_01 9:08

Oh, that's a vital distinction.

SPEAKER_00 9:09

Yeah. SGLT2 inhibitors reduce intraclamerular pressure and alter myocardial metabolism in ways that are entirely uncoupled from their glykemic effects.

SPEAKER_01 9:17

So you do not stop them just because the blood glucose is beautifully controlled.

SPEAKER_00 9:21

No, you're relying on them to protect the nephrons and the myocardium.

SPEAKER_01 9:24

And while we are talking about diabetes, we should explicitly underline this. Never ever attempt deprescribing in type 1 diabetes or latent autoimmune diabetes in adults' LADA without the direct involvement of the patient's endocrinologist or diabetes care team.

SPEAKER_00 9:40

Absolutely non-negotiable. The risk of rapid diabetic ketoacidosis is just too severe.

SPEAKER_01 9:45

So we've cleared the red flags, we've respected the specialist boundaries, the driving laws, and the absolute contraindications. What we are left with as general practitioners is the vast bulk of the medication list.

SPEAKER_00 9:56

Aaron Powell The day-to-day prescribing cascades.

SPEAKER_01 9:59

Yes. And here's where it gets really interesting. How do we physically step these doses down? Because the pharmacokinetics of de-prescribing vary wildly. We have drugs that can be stopped cold turkey, and we have drugs that require the most meticulous, painstaking mechanics to avoid physiological chaos.

SPEAKER_00 10:15

Let's start with the no-tapper list. These are the clinically satisfying ones.

SPEAKER_01 10:18

The easy wins.

SPEAKER_00 10:18

Yeah. If a patient's levels are fined, you can generally cease iron in B12 without tapering.

SPEAKER_01 10:24

And the biological reason for that is simple. The body has extensive storage capacity for these. The liver stores B12 for years, and iron is sequestered in the reticuloendothelial system. Right. When you stop the oral supplement, there is no sudden serum crash or receptor shock. The stores just slowly deplete over months.

SPEAKER_00 10:44

Precisely. Oral diabetes agents can also generally be stopped without a taper, but you must prioritize stopping insulin and sulfanulureas first.

SPEAKER_01 10:53

Because of the hypos.

SPEAKER_00 10:54

Yes. The pharmacokinetics of sulfonylureas, particularly in older adults with declining renal function, create a severe, prolonged risk of hypoglykemia.

SPEAKER_01 11:03

What about loop diuretics?

SPEAKER_00 11:04

Low dose ferrosamide, meaning less than 40 milligrams daily, can also usually just be stopped.

SPEAKER_01 11:09

Yeah, just stopped cold.

SPEAKER_00 11:11

Yeah, at that low dose, the nephrons in the loop of Henla can typically autoregulate the sodium and water reabsorption without triggering massive fluid shifts.

SPEAKER_01 11:19

Good to know. And what about calcium and vitamin D? That is a massive combination on almost every aged care list we review.

SPEAKER_00 11:26

Ah, this requires a crucial demographic distinction. You can seize calcium and vitamin D without a taper. But this only applies to community-dwelling adults.

SPEAKER_01 11:36

Okay.

SPEAKER_00 11:36

And specifically those with adequate dietary intakes, over 1,300 milligrams a day, or a serum 25OH vitamin D level consistently at or above 15 nanomoles per liter.

SPEAKER_01 11:49

But the rules change completely if they cross the threshold into a nursing home.

SPEAKER_00 11:53

Yes, entirely. If your patient is in residential aged care, ongoing treatment is universally recommended. The baseline risk of falls, minimal sun exposure, and subsequent fractures in that environment is so high that the preventative benefit remains continuously relevant.

SPEAKER_01 12:07

So, community dwelling with good levels, you can prune it. Residential aged care, keep it on the chart. That's a very clear line in the sand.

SPEAKER_00 12:14

Exactly.

SPEAKER_01 12:15

Now let's move away from the easy stops and into the meticulous tapers, the ones where the biological mechanics dictate the math. I always struggle with colinesterase inhibitors in dementia patients.

SPEAKER_00 12:25

They're tough. The family's often terrified that if we stop the aerosept, their parent will deteriorate overnight.

SPEAKER_01 12:30

So how do you biologically step that down without triggering a crisis?

SPEAKER_00 12:35

Aaron Ross Powell Well, the brain is adapted to the artificially elevated acetylcholine levels by downregulating its own receptors. If you stop abruptly, you induce a sudden cholinergic deficit.

SPEAKER_01 12:46

Which leads to rapid cognitive and functional decline.

SPEAKER_00 12:49

Right. So the the protocol is to have the daily dose every four weeks.

SPEAKER_01 12:52

Aaron Powell Every four weeks. That is a painstakingly slow step down.

SPEAKER_00 12:56

It has to be. And before you initiate the next drop, you must formally ensure there has been no worsening of cognition, no emergence of agitation or apathy, and no decline in their activities of daily living. And then once you safely reach half of the lowest standard dose formulation, you can cease it completely. Got it.

SPEAKER_01 13:13

And then we have the gut. Proton pump inhibitors, I feel like every second patient over 60 is on a PPI, often started a decade ago for a brief stint of dyspepsia and just, you know, never reviewed.

SPEAKER_00 13:24

PPIs are notorious for rebound acid hypersecretion.

SPEAKER_01 13:27

Why is this?

SPEAKER_00 13:28

When you chemically suppress acid production for years, the body compensates by ramping up gastrin production. This causes the parietal cells in the stomach lining to physically hypertrophy.

SPEAKER_01 13:39

They actually grow larger.

SPEAKER_00 13:40

They grow larger and more numerous. If you stop the PPI abruptly, those massive parietal cells are suddenly uninhibited, and the stomach floods with massive amounts of acid.

SPEAKER_01 13:51

It's essentially an acid tsunami, and the patient ends up in agony convinced their ulcer is back.

SPEAKER_00 13:57

Exactly why the precise mechanic here is a 50% dose reduction every two weeks to let those parietal cells slowly shrink back to baseline.

SPEAKER_01 14:08

And what about the physical tablets?

SPEAKER_00 14:10

Oh, importantly, you must tell the patient not to physically break enteric coded formulations, as that destroys the delivery mechanism. Once you hit half the lowest standard dose, you can switch to alternate day dosing or move to purely on-demand use.

SPEAKER_01 14:24

Let's talk about high dose furosomide. Say someone is on 80 to 160 milligrams a day, but their heart failure has been beautifully compensated for a long time. We know we can stop the 40 milligram dose cold, but we can't do that with 160.

SPEAKER_00 14:38

No way. With high doses, the kidneys have heavily adapted to the diuretic blockade. For 80 to 160 milligrams, you reduce the dose by 40 milligrams every two weeks until they reach that 40 milligram floor.

SPEAKER_01 14:52

And once they hit 40?

SPEAKER_00 14:53

Once they're at 40 milligrams, you have it for a week and then cease. And obviously, you're closely monitoring daily weight and fluid status throughout that process for any signs of third spacing.

SPEAKER_01 15:05

And anti-gout therapies like allopyrinol.

SPEAKER_00 15:08

You only even consider deprescribing this if the patient has been in strict clinical remission for at least one year.

SPEAKER_01 15:14

Okay, one year.

SPEAKER_00 15:15

And their serum urate must be strictly below 0.36 millimoles per liter. If they meet that criteria, you have the dose every two weeks.

SPEAKER_01 15:24

Because if you drop it too fast.

SPEAKER_00 15:25

You destabilize the uric acid in the blood, which can mobilize existing microstopic crystals in the joints and trigger a massive acute flare.

SPEAKER_01 15:33

Right. Okay. That brings us to the most notoriously difficult taper in general practice: benzodiazepines.

SPEAKER_00 15:39

The big one.

SPEAKER_01 15:40

I always explain tapering denzos to my registrar is like slowly depressurizing a commercial airplane cabin.

SPEAKER_00 15:46

That's a brilliant way to put it.

SPEAKER_01 15:47

If you're flying at 30,000 feet and you suddenly blow the door open, the physiological chaos is violent, immediate, and catastrophic. You have to bring the pressure down so slowly that the body barely registers the change in altitude.

SPEAKER_00 16:00

And the biology perfectly mirrors that analogy. Prolonged benzodiazpine use changes the actual physical conformation and number of GABA receptors in the central nervous system.

SPEAKER_01 16:11

The brain relies on the drug to provide its inhibitory braking system.

SPEAKER_00 16:15

Exactly. If you stop abruptly, the brain is left completely uninhibited, flooded with excitatory glutamate. This leads to severe rebound anxiety, tremors, profound agitation, and a high risk of withdrawal seizures.

SPEAKER_01 16:28

So what is the mathematical protocol to prevent that excitatory storm?

SPEAKER_00 16:33

For standard use, you reduce the dose by 25% every one to four weeks.

SPEAKER_01 16:37

But realistically, how often do patients actually tolerate a 25% drop if they've been on diazepam for 20 years or if they've had a traumatic failed taper in the past?

SPEAKER_00 16:46

Rarely. For those high-risk patients, a 25% drop is far too aggressive. You have to go painstakingly slow.

SPEAKER_01 16:53

How slow are we talking?

SPEAKER_00 16:54

We're talking 5 to 10% reductions at intervals of four weeks or more. Wow. To achieve that practically, you often have to prescribe liquid formulations or utilize compounding pharmacies to get precise doses that fall well below half the lowest commercially available strength. It is a neurochemical marathon, not a sprint.

SPEAKER_01 17:14

This highlights perfectly that the physical taper isn't the finish line. In fact, once the dose finally hits zero, that's arguably when the GP's diagnostic safety netting really begins, which leads us into monitoring and managing post-deprescribing complications.

SPEAKER_00 17:30

Because when a patient comes back into the clinic three weeks post-taper and says, Doctor, I feel absolutely awful, the GP faces a critical diagnostic fork in the road.

SPEAKER_01 17:38

Right. It's not always just withdrawal.

SPEAKER_00 17:40

No. You have to distinguish between three distinct physiological possibilities. Number one, is this disease recurrence? Meaning, has the underlying condition simply unmasked itself because we removed the treatment?

SPEAKER_01 17:53

Okay, what's number two?

SPEAKER_00 17:54

Number two, is this an unrelated new diagnosis that just happens to be occurring simultaneously? Or number three, is this a true adverse drug withdrawal event in ADWE?

SPEAKER_01 18:06

And the treatment pathway for those three things is entirely different. If it's a true ADWE, we might need to simply slow the taper, provide symptomatic support, and write it out.

SPEAKER_00 18:16

Precisely.

SPEAKER_01 18:17

What are some specific high-yield ADWE callouts that GPs need to have on their radar?

SPEAKER_00 18:22

A really vital one is proclorperizine, commonly used for dizziness or nausea.

SPEAKER_01 18:27

Stimule.

SPEAKER_00 18:27

Yes. Because it is a strong dopamine antagonist, long-term use causes dopamine receptor supersensitivity in the brain. If you taper someone off this quickly, you must explicitly watch for withdrawal-emergent abnormal movements.

SPEAKER_01 18:41

Like severe extrapyramidal phenomena, tardive dyskinesia.

SPEAKER_00 18:44

Exactly. If these occur and are persistent, you shouldn't just wait it out in the clinic. You need to actively collaborate with a physiotherapist or a speech pathologist if swallowing is compromised.

SPEAKER_01 18:54

That's an excellent pickup. It's not just about the vertigo returning, it's the neurological fallout. And we touched on the mechanism earlier, but PPIs are another massive culprit for ADWEs due to that parietal cell hypertrophy.

SPEAKER_00 19:07

Yeah, the key clinical timeline for GPs to remember is that this rebound acid hypersecretion doesn't happen on day two. It typically hits its peak within four to eight weeks of cessation.

SPEAKER_01 19:18

So you have to preempt that with the patient.

SPEAKER_00 19:20

You have to actively warn them during the taper. Say, look, you might get some intense heartburn around week four or five. Doesn't mean your original ulcer is back. It means your stomach lining is readjusting.

SPEAKER_01 19:30

And how do we manage that window?

SPEAKER_00 19:32

You manage that specific window with rescue antacids or Lginates, not by immediately jumping back to the daily PPI prescription.

SPEAKER_01 19:39

So what does this all mean for the everyday workflow in the clinic? Let's synthesize the core GP monitoring schedule. If a registrar asks you, when do I physically need to see this patient next? What is the rule of thumb?

SPEAKER_00 19:51

The general safety framework is to review the patient in the clinic every one to two weeks after every single dose reduction. You maintain that tight cadence up until at least four weeks post-cessation.

SPEAKER_01 20:04

But with the specific exception for PPIs, given that delayed acid rebound.

SPEAKER_00 20:09

Correct. For PPIs, you need to extend that intensive monitoring window and patient education for a full eight weeks post-cessation.

SPEAKER_01 20:17

And what about laboratory monitoring? I mean, we aren't just relying on subjective symptoms. We need objective pathological data to ensure we haven't biologically destabilized them.

SPEAKER_00 20:26

Aaron Powell The lab timing has to align with the physiological half-lives and cellular cycles.

SPEAKER_01 20:31

Right.

SPEAKER_00 20:31

For diabetes medications, you want to check an HBA1C at three months post-taper. Because the red blood cell lifespan is about 120 days. Checking it earlier won't give you a true reflection of their new glycemic baseline.

SPEAKER_01 20:42

Aaron Powell Makes sense. And for the supplements.

SPEAKER_00 20:45

For iron B12, if you cease those supplements, you schedule a full blood count and iron studies at 11 months post-discontinuation.

SPEAKER_01 20:52

I love that specific timeline, 11 months. It is perfectly strategic because it aligns directly with the MBS, the Medicare Benefit Schedule, for the annual preventative health assessments in order Australians.

SPEAKER_00 21:04

Exactly. It's highly practical for billing and recall systems. Unless, of course, the patient becomes actively symptomatic with fatigue, pallor, or glossitis sooner, in which case you test immediately.

SPEAKER_01 21:15

Aaron Powell Obviously. But this raises an important question, though, about the psychology of deprescribing. What happens if they do become symptomatic? What if the HBA1C spikes to 9%, or the blood pressure climbs back to 160, or the rebound anxiety becomes genuinely unbearable despite a 5% taper? What if the patient essentially fails the taper?

SPEAKER_00 21:36

Aaron Powell I think we need to completely banish the word failure from the deprescribing vocabulary, both for the patient and the clinician.

SPEAKER_01 21:42

I agree entirely.

SPEAKER_00 21:43

Restarting a medication at the lowest effective dose is not a failure of deprescribing. It is the very definition of dynamic responsive medicine. You ran a carefully monitored clinical trial of one.

SPEAKER_01 21:53

You gathered objective data.

SPEAKER_00 21:55

Yes. You safely found the patient's physiological floor. If they generally Need a small dose of a medication to maintain their quality of life and physiological stability, then you prescribe it with confidence, knowing it's absolutely necessary and no longer just a historical habit on a script pad.

SPEAKER_01 22:12

You've documented the clinical rationale, you've engaged the patient in their own care, and you found their exact threshold. That is brilliant high-level medicine. It really is. Thank you for this incredibly precise breakdown today. The physiological mechanisms, the exact dosing timelines, the MBS alignments, this is exactly the kind of actionable data GPs and registrars need to take back to the clinic tomorrow morning. Deprescribing isn't just passively stopping a drug, it is an active, vital clinical skill that requires immense vigilance.

SPEAKER_00 22:44

It's arguably one of the most pharmacologically complex things we do in primary care, balancing all these competing physiological systems in an aging body.

SPEAKER_01 22:51

Which leaves us with a final thought to ponder as we wrap up this deep dive. Throughout our medical training, we spend years, literally thousands of hours in lecture halls and hospital wards, having algorithms drilled into our heads about exactly how and when to start medications.

SPEAKER_00 23:06

We are exceptionally good at initiating therapy.

SPEAKER_01 23:08

Right. But what if the true hallmark of a master clinician isn't just knowing what to prescribe, but knowing exactly how to safely and strategically dismantle a prescribing cascade? Imagine if we dedicated as many hours in our registrar training to the pharmacokinetics of de-prescribing as we do to prescribing.

SPEAKER_00 23:27

That would be revolutionary.

SPEAKER_01 23:28

How would that transform the landscape of polypharmacy and falls risk for the next generation of older Australians?

SPEAKER_00 23:35

It would completely shift the paradigm of aging and primary care.

SPEAKER_01 23:38

Thank you all for joining us on this deep dive. We encourage you to take these exact numbers, these physiological mechanisms, and this specific framework into your next clinic session. Remember, you aren't just hacking away at the medication list. You are carefully, strategically pruning the tree, making sure the core trunk stays robust and structurally sound for years to come. See you next time.